This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (3)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Topic Collections  • Cardiovascular System  • Cardiovascular Disease/ Myocardial Infarction  • Alert me on articles by topic  Social Bookmarking   What's this?

Is Science Catching Up With Practice?

Mauricio G. Cohen, MD; E. Magnus Ohman, MD

JAMA. 2005;293:2154-2156.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In the last 3 to 4 years, the use of drug-eluting stents in clinical practice has revolutionized interventional cardiology. Two pivotal trials using sirolimus- and paclitaxel-eluting stents and reporting previously unheard-of single-digit restenosis rates^1-2 heralded a new era for interventional cardiology, suggesting that the most vexing problem for intervention, namely, restenosis, had finally been tackled. These 2 trials predominantly studied patients undergoing elective procedures and found target-lesion revascularization rates of approximately 3% to 4% and postprocedure myocardial infarction rates that ranged from 2.8% to 3.5%.

In the United States, drug-eluting stents were approved by the Food and Drug Administration in April 2003, after approximately 90 000 sirolimus-eluting stents had been distributed outside the United States.³ Despite the fact that simple lesions in low-risk patients were studied in the clinical trials that led to approval of these devices in the United States, the adoption . . . [Full Text of this Article]

Author Affiliations: Division of Cardiology, University of North Carolina at Chapel Hill (Drs Cohen and Ohman)

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

Tirofiban and Sirolimus-Eluting Stent vs Abciximab and Bare-Metal Stent for Acute Myocardial Infarction: A Randomized Trial
Marco Valgimigli, Gianfranco Percoco, Patrizia Malagutti, Gianluca Campo, Fabrizio Ferrari, Dario Barbieri, Giordano Cicchitelli, Eugène P. McFadden, Fabia Merlini, Lucia Ansani, Gabriele Guardigli, Alessandro Bettini, Giovanni Parrinello, Eric Boersma, Roberto Ferrari, and for the STRATEGY Investigators
JAMA. 2005;293(17):2109-2117.
ABSTRACT | FULL TEXT  

Incidence, Predictors, and Outcome of Thrombosis After Successful Implantation of Drug-Eluting Stents
Ioannis Iakovou, Thomas Schmidt, Erminio Bonizzoni, Lei Ge, Giuseppe M. Sangiorgi, Goran Stankovic, Flavio Airoldi, Alaide Chieffo, Matteo Montorfano, Mauro Carlino, Iassen Michev, Nicola Corvaja, Carlo Briguori, Ulrich Gerckens, Eberhard Grube, and Antonio Colombo
JAMA. 2005;293(17):2126-2130.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Myocardial Revascularization after Acute Myocardial Infarction
George and Oz
Card Surg Adult 2008;3:669-696.
FULL TEXT  

Haemodynamic significance of ostial side branch nipping following percutaneous intervention at bifurcations: a pressure wire pilot study
Bellenger et al.
Heart 2007;93:249-250.
FULL TEXT  

Randomized Double-Blind Comparison of Sirolimus-Eluting Stent Versus Bare-Metal Stent Implantation in Diseased Saphenous Vein Grafts: Six-Month Angiographic, Intravascular Ultrasound, and Clinical Follow-Up of the RRISC Trial
Vermeersch et al.
J Am Coll Cardiol 2006;48:2423-2431.
ABSTRACT | FULL TEXT  

Patterns of restenosis after drug-eluting stent implantation: insights from a contemporary and comparative analysis of sirolimus- and paclitaxel-eluting stents
Corbett et al.
Eur Heart J 2006;27:2330-2337.
ABSTRACT | FULL TEXT  

To Cath or Not to Cath: That Is No Longer the Question
Bhatt
JAMA 2005;293:2935-2937.
FULL TEXT  

A Low-Cost Strategy for Primary PCI?
Journal Watch Cardiology 2005;2005:2-2.
FULL TEXT